"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM

I-SPY Email List Sign-up

Featured News

Dr. Laura Esserman Honored: OncLive® To Induct the 2018 Class of Giants of Cancer Care®

Announcement

May 26, 2018

SABCS 2017: Long-term efficacy results from the I-SPY 2 TRIAL indicate pathological complete response (pCR) is a powerful predictor for breast cancer survival

Press Release

December 7, 2017

New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck’s KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer

Press Release

June 5, 2017

-- more news --

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.

1300

patients enrolled

16

agents completed
evaluation since 2010

3

agents received
accelerated approval

World-class science requires world-class scientists

Meet some of our team

Christopher Benz

Medical Oncologist

University of California, San Francisco

Professor, Dept of Biostatistics

University of Texas MD Anderson Cancer Center

Chair of Informatics WG, Chief Data Officer, Quantum Leap Healthcare Collaborative

Medical Oncologist

Swedish Cancer Institute

Don't miss a thing! Get I-SPY results, news and event information delivered right to your inbox.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

I-SPY is supported by: